ARCH Venture Management as of Sept. 30, 2025
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 9 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Rapport Therapeutics (RAPP) | 22.5 | $111M | 3.7M | 29.70 | |
| Beam Therapeutics (BEAM) | 22.4 | $110M | 4.5M | 24.27 | |
| Maze Therapeatics (MAZE) | 21.7 | $107M | 4.1M | 25.93 | |
| Vir Biotechnology (VIR) | 15.0 | $74M | 13M | 5.71 | |
| Lyell Immunopharma Com New (LYEL) | 9.1 | $45M | 2.8M | 16.24 | |
| Erasca (ERAS) | 4.9 | $24M | 11M | 2.18 | |
| Gossamer Bio (GOSS) | 4.3 | $21M | 8.1M | 2.63 | |
| Q32 Bio (QTTB) | 0.1 | $635k | 321k | 1.98 | |
| Cero Therapeutics Hldgs (CERO) | 0.0 | $114k | 22k | 5.09 |
